Washington University Department of Neurology
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Naismith, Robert T
CELLO, NCT04877457: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

Terminated
4
3
US
Ocrelizumab, Placebo
Yale University, Genentech, Inc.
Radiologically Isolated Syndrome, Multiple Sclerosis
06/23
06/23
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Recruiting
3
2060
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
Dula, Courtney
No trials found

Download Options